INSYS Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From INSYS Therapeutics, Inc.
As fears about vaccine escape grow, test manufacturers have been quick to assert that their tests can spot the new Omicron variant of SARS-CoV-2
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.
The US Food and Drug Administration has taken additional steps to ensure mutations of the COVID-19 virus do not negatively impact the efficacy of tests.
- Drug Delivery
- Other Names / Subsidiaries
- NeoPharm, Inc.
- Fresenius Biotech GmbH
- Neovii Biotech GmbH